Rationale: Studies in transgenic mice showed the key role of (Pim-1) (proviral integration site for Moloney murine leukemia virus-1) in the control of cardiomyocyte function and viability.
transcription 3 (STAT3) and protein kinase B (PKB/Akt), 6 which act as modulators of insulin and nutritional status in the heart 10 and are both downregulated in models of diabetic cardiomyopathy. 11 On the other hand, Pim-1 is inactivated by protein phosphatase 2A (PP2A) 12 and constitutes a direct inhibitory target of microRNA-1 (miR-1). 13 However, no information is available on whether PP2A and miR-1 may inhibit Pim-1-associated signaling in the diabetic heart.
The objective of the present study was to explore whether an unbalanced prevalence of negative regulators of Pim-1 could result in the downregulation of prosurvival signaling in diabetic hearts. We also investigated whether forced expression of Pim-1 could inhibit the progression of cardiomyopathy. To this second aim, we used the adeno-associated virus serotype-9 (AAV9), which reportedly allows efficient global cardiac gene transfer after systemic injection. 14 -16 Methods An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Ethics
Experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources, 1996) and with approval of the British Home Office and the University of Bristol. Type-1 DM was induced in male CD1 mice (Charles River, Margate, United Kingdom) by injection of streptozotocin (STZ; 40 mg/kg body weight IP per day for 5 days). 11 DM was confirmed by regular measurements of blood glucose levels (Online Figure I ).
Biochemical Measurements
Serum insulin (Millipore, Billerica, MA), cholesterol (Biovision, Mountain View, CA), triglycerides (Biovision), and cortisol (R&D Systems, Minneapolis, MN) were measured with ELISA kits.
In Vivo AAV9 -hPIM-1 Gene Transfer
AAV9 -Pim-1 was prepared by a cross-packaging approach, in which the human (h) Pim-1 gene (hPIM-1) was packaged into adeno-associated virus capsid serotype-9 as described previously. 15, 17 Four weeks after DM induction, mice manifesting diastolic dysfunction, as assessed by pulsed Doppler analysis of mitral valve velocity, 11 were randomly assigned to receive AAV9 -hPIM-1 (1ϫ10 10 or 5ϫ10 10 genome copies [gc] per animal) or AAV9 -␤galactosidase (␤-gal) through the tail vein under aseptic precautions; age-matched animals that received STZ-vehicle served as nondiabetic controls (nϭ16 in each group).
Hemodynamic Measurements
Dimensional and functional parameters were measured with a high-frequency, high-resolution echocardiography system (Vevo 770, VisualSonics, Toronto, Canada; nϭ14 per group) as described previously. 11, 18 Left ventricular (LV) pressure (nϭ12 per group) was measured with a 1.4F Millar catheter (Millar Instruments, Houston, TX) before animals were euthanized. Myocardial blood flow was assessed with fluorescent microspheres, which were injected into the LV cavity (nϭ6 per group). 11, 18 Immunohistochemistry For immunohistochemistry, 5-m-thick LV cryostat sections were stained with specific antibodies and analyzed with fluorescence microscopy. Superoxides were revealed with dihydroethidium staining of 20-m-thick LV cryostat sections (nϭ6 per group). 11, 18 In Vitro Studies
Isolation and Culture of Adult Cardiomyocytes and CPCs
Cardiomyocytes were isolated from the ventricles of 8-week-old male Wistar rats. Murine cardiomyocytes (HL-1 line), a generous gift from Dr William Claycomb (Louisiana State University Medical Center, New Orleans), were cultured as described previously. 18 CPCs from murine hearts were extracted with a commercially available isolation kit (Millipore; Online Figure II ).
Prosurvival Effect of Pim-1 on Cardiomyocytes and CPCs Exposed to High Glucose
To simulate the diabetic condition, cardiomyocytes or CPCs were cultured in the presence of high D-glucose (HG; 30 mmol/L) or normal D-glucose (NG; 5 mmol/L) with D-mannitol (25 mmol/L) added as an osmotic control. Twenty-four hours before the HG challenge, cells were transfected either with hPIM-1 plasmid (8 g/1ϫ10 6 cells) or with anti-miR-1 (50 nmol/L; Applied Biosystems, Foster City, CA) with a commercially available transfection agent (lipofectamine 2000, Invitrogen, Carlsbad, CA). Expression of the hPim-1 transgene was identified with an antibody that specifically recognizes the human protein (Online Figure III) . The transfection efficacy with this technique was 65Ϯ8%. Effective miR-1 inhibition was verified in pilot titration experiments (Online Figure  IV) . Null vector or scrambled sequence was used as negative control for hPIM-1 plasmid and anti-miR-1, respectively. At the end of 48 hours of HG exposure, cells were collected for measurement of caspase-3/7, caspase-8, and caspase-9 activity (all from Promega, Madison, WI) and for immunoblotting and immunocytochemistry analysis. All experiments were performed in triplicate and repeated 5 times.
RNA Isolation and Semiquantitative RT-PCR
Total RNA was isolated from flash-frozen LV myocardium at different time points after DM induction with TRIzol (Invitrogen) according to the manufacturer's instructions. RT-PCR was performed according to the standard protocol described previously. 11, 18 
Protein Extraction and Western Blotting
Proteins were extracted from LV samples, cardiomyocytes, and CPCs and used for Western blotting as described previously. 11, 18 
Statistical Analysis
Comparison of multiple groups was performed by analysis of variance. Two-group analysis was performed by Student t test. Values were expressed as meansϮSEM. PϽ0.05 was considered significant. 
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Results
Upregulation of Pim-1 Inhibitors in Diabetic Hearts
We previously documented that diabetic cardiomyopathy is characterized from the early stage by reduction of Pim-1, along with downregulation of its activators, p-STAT3 (STAT3-p-Tyr705) and p-Akt (Akt-p-Ser473), and O-GlcNAc modification of Akt, which results in reduction of Akt activity. 11 Here, we newly show that the decline of cardiac function in diabetic mice ( Figure 1A) is associated with upregulation of PP2A ( Figure 1B ), a phosphatase that reportedly dephosphorylates and inactivates Pim-1. 12 Furthermore, Pim-1 represents a validated inhibitory target for the muscle-specific miR-1, 13 a microRNA implicated in cardiac remodeling, metabolic signaling, and arrhythmogenesis. 19 Notably, we found that miR-1 is upregulated from the early phase (3-fold at 4 weeks after DM induction, PϽ0.05 versus healthy mice) and increases further during progression of diabetic cardiomyopathy (6-fold at 20 weeks, PϽ0.001; Figure 1C ). Thus, an unbalance between negative and positive regulators leads to Pim-1 downregulation with advancing cardiomyopathy.
Forced Pim-1 Expression Prevents HG-Induced Cardiomyocyte Apoptosis
We next verified whether Pim-1 could counteract the negative influence of HG on cardiomyocyte viability. To this aim, adult rat cardiomyocytes were cultured under NG or HG conditions after transfection with hPIM-1 plasmid or anti-miR-1. As expected, HG significantly reduced the expression of Pim-1 as assessed by immunocytochemistry ( 
Successful Transduction of Diabetic Hearts With Human Pim-1 After Systemic AAV9 -Pim-1 Administration
To verify whether cardiac-specific expression of Pim-1 protects diabetic mice from cardiomyopathy, we constructed a new AAV9 vector carrying the hPIM-1 gene. Effective transduction and duration of transgene expression were analyzed by Western blot ( Figure 3A ) and immunohistochemistry ( Figure 3B ). Hearts from mice that received the AAV9 -␤-gal (viral vector control) were negative for immunoreactive hPim-1, whereas intravenous injection of AAV9 -hPIM-1 resulted in robust and persistent expression of hPim-1 beginning 2 weeks after injection and becoming stable after 6 weeks (middle lane in Figure 3Ai ). Using an antibody that does not distinguish between mouse (mPim-1) and human (hPim-1) Pim-1, we confirmed the decline of Pim-1 levels in hearts of AAV9 -␤-gal-injected diabetic mice (PϽ0.01 versus time 0; upper lane in Figure 3Ai and Figure 3Aii ). 11 Conversely, we observed a marked increase in cardiac Pim-1 after AAV9 -hPIM-1 injection that led to levels 10-fold higher than those of AAV9 -␤-gal-injected controls 
Effect of AAV9 -hPIM-1 Gene Therapy on General Health and Cardiac Function
Diabetic mice showed a decrease in body weight, which was prevented by AAV9 -Pim-1 gene therapy ( Figure 4A ). No treatment effect was observed in diabetic mice with regard to serum insulin, cholesterol, and cortisol; however, AAV9 -Pim-1 reduced triglyceride levels (Online Figure IX) . Consistent with our previous study, 11 echocardiography and pulsed Doppler analyses revealed a decrease in the E/A ratio at 4 weeks after DM induction, indicative of diastolic dysfunction, whereas contractility was preserved ( Figures 4B and 4C ). At this early phase of cardiomyopathy, diabetic mice were randomly allocated to treatment with AAV9-␤-gal or AAV9-hPIM-1 (1ϫ10 10 or 5ϫ10 10 gc). Subsequent follow-up demonstrated the steady decline of the E/A ratio in AAV9-␤-gal-treated diabetic mice, whereas forced expression of hPIM-1 inhibited this trend, which resulted in improved diastolic function at late time points, with no difference between the 2 doses ( Figure 4B , which shows the results of a low dosage; PϽ0.01 versus AAV9-␤-gal). Mice developed systolic dysfunction beginning after 12 weeks of DM, as indicated by the reduction in LV ejection fraction, cardiac output, and fractional shortening (Figures 4Ci through 4Ciii ).
Furthermore, at late stages, they manifested LV chamber enlargement (Figures 4Civ and 4Cv ) and a reduced ratio of LV anterior wall thickness to LV internal diameter at end diastole ( Figure 4Cvi ). Analysis with the Millar transducer showed an increase in LV end-diastolic pressure and a decrease in LV end-systolic pressure, dP/dt max , and dP/dt min in diabetic mice ( Figure 4D ), which confirmed the typical hemodynamic characteristics of heart failure. Analysis of pressure-volume loops further verified the marked dysfunction of diabetic hearts ( Figure 4E ). In contrast, forced expression of hPIM-1 resulted in a global improvement of LV performance, pressure indices, volumes, and wall thickness/internal diameter ratio ( Figures 4C through 4E ; PϽ0.01 versus AAV9-␤gal-treated mice for all comparisons). 
Anatomic Correlates of Pim-1-Induced Cardioprotection
Cardiomyocyte loss by apoptosis and interstitial fibrosis are typical features of diabetic cardiomyopathy and account for the inotropic deficit and diminished LV compliance, respectively. We confirmed that DM increases cardiomyocyte apoptosis, as assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling staining ( Figure 5A ; PϽ0.001 versus healthy mice), and interstitial fibrosis, as evidenced by Sirius red staining ( Figure 5B ; PϽ0.01 versus healthy mice), with both effects being remarkably blunted by AAV9 -Pim-1 ( Figure  5 ; PϽ0.01 versus AAV9 -␤-gal for both comparisons). Furthermore, diabetic cardiomyopathy consistently has been associated with microangiopathy in the absence of coronary artery disease. 20 As shown in Figure 5C , myocardial perfusion was reduced by DM, and this defect was prevented by AAV9 -hPIM-1 (PϽ0.01 versus AAV9 -␤gal). Concordantly, the high dose of AAV9 -Pim-1 attenuated the DM-induced decrease in capillary density (PϽ0.01 versus Figure 5D ).
Molecular Mechanisms of Pim-1-Induced Cardioprotection
Next, we verified the signaling pathways implicated in the beneficial effect of Pim-1 on cardiomyocyte survival and inotropism. Forced expression of hPim-1 increased the levels of pBad, which inhibits proapoptotic caspase-3 by preserving the levels of antiapoptotic Bcl-2 ( Figure 6A ; PϽ0.01 versus AAV9 -␤-gal for all comparisons). A recent study showed that Pim-1 confers cardiomyocytes with mitochondrial resistance after oxidative stress challenge through preservation of the inner mitochondrial membrane potential. 7 We show for the first time that Pim-1 overexpression results in a remarkable reduction in reactive oxygen species levels in diabetic myocardium ( Figure  6B ; PϽ0.01 versus AAV9 -␤-gal). In contrast, AAV9 -hPIM-1 did not affect the DM-induced reduction in pAkt and Akt activity, which confirms that Pim-1 acts down-stream of Akt ( Figure 6C ). Accordingly, there was no change in the other upstream regulators of Pim-1, such as STAT3, PP2A ( Figure 6C ), and miR-1 (data not shown) after AAV9 -Pim-1 compared with AAV9 -␤-gal. The sarcoplasmic reticulum regulates cardiac contractility through modulation of Ca 2ϩ uptake, which is dysfunctional in DM. 21 Importantly, forced expression of Pim-1 prevented the decrease of sarcoendoplasmic reticulum Ca 2ϩ -ATPase in diabetic hearts ( Figure 6C ). Furthermore, the inotropic decline of the diabetic heart was attributed to a switch in the relative proportion of the 2 isoforms of myosin heavy chain (MHC), with the ␤-MHC isoform becoming the dominant heart isozyme. 22 Importantly, PIM-1 gene therapy blunted the reduction of the ␣-MHC to ␤-MHC ratio in diabetic hearts ( Figure 6C ).
Pim-1 Overexpression Preserves CPC Viability and Proliferative Activity
Diabetic cardiomyopathy is reportedly associated with the progressive exhaustion of resident CPCs, which fail to compensate for the continuous loss of cardiomyocytes. 23 Exposure of murine Sca-1 ϩ CPCs to HG resulted in the reduction of Pim-1, pBad, and Bcl-2 and in the activation of caspase-3 ( Figure 7A ; PϽ0.01 versus NG for all comparisons), which replicated the expressional changes induced by DM or HG in mature cardiomyocytes. In addition, HG caused a 60% reduction in Sca-1 ϩ CPC proliferation ( Figure 7B ; PϽ0.001 versus NG). Importantly, overexpression of hPIM-1 restored prosurvival signaling and the proliferative activity of CPCs in vitro ( Figures 7A and 7B ). The same effect was observed after inhibition of miR-1 by anti-miR1 ( Figures 7C  and 7D ).
Immunohistochemistry analysis of diabetic hearts confirmed the reduction of c-kit ϩ cells and showed an increase in the fraction of senescent CPCs, assessed as c-kit ϩ Ki67 Ϫ cells that showed high ␥-H2A.X foci density. Pim-1 gene therapy specifically increased the prevalence of lineage-committed ␣-SA ϩ c-kit ϩ cells and reduced the proportion of c-kit ϩ cells that expressed the senescence marker ( Figure 7E ). Furthermore, DM induced a marked reduction in the proliferative ability of cardiomyocytes, as assessed by Ki-67 and PCNA, compared with healthy controls. In contrast, forced expression of hPIM-1 caused a remarkable increase in the number of Ki-67 ϩ (Figure 7F -i) and PCNA ϩ (Online Figure X) cardiomyocytes in diabetic hearts. Interestingly, hPIM-1 also increased the number of Ki-67 ϩ c-kit ϩ cells in the diabetic heart ( Figure 7F -ii).
Discussion
This study illustrates a previously unrecognized mechanism that accounts for the propensity of cardiac cells to undergo apoptosis in a mouse model of type 1 DM, through inhibition of Pim-1 by miR-1 and PP2A and the lack of positive modulation by STAT3 and Akt. We also show that cardiacspecific Pim-1 gene therapy halts the progression of diabetic cardiomyopathy.
Previous work from Sussman's group 6 indicates that Pim-1 is a crucial component of the signaling machinery that counteracts cardiomyocyte apoptosis during the early phase of postischemic healing. In addition, Pim-1 is upregulated in failing hearts as an extreme, inefficient attempt to preserve cardiac function. 5 At variance with those results, we report here that Pim-1 is downregulated beginning in the early phase of diabetic cardiomyopathy and steadily decreases through the progression of contractile dysfunction and heart failure. The accrual of alterations of upstream Pim-1 activators 11 and, as reported for the first time here, the upregulation of Pim-1 inhibitors PP2A and miR-1 explain the peculiar behavior observed in hearts of diabetic mice compared with ischemic or pressure-overload models. It is noteworthy that increased levels of ceramide in diabetic myocardium could be a possible mechanism behind the upregulation of PP2A, 12 although this requires further investigation.
Muscle-specific microRNAs, such as the bicistronic miR-1 and miR-133 cluster, have been implicated in myocardial and cardiac stem cell development, cardiac hypertrophy, and remodeling. In particular, miR-1 negatively regulates the expression of hypertrophy-associated genes such as IGF-1 (insulin-like growth factor-1), calmodulin, and Mef-2a (myocyte enhancer factor 2a). 19, 24 Importantly, recent studies report that HG induces miR-1 activation in the rat cardiac H9c2 cell line via upregulation of miR-1 transcriptional regulator serum response factor. 25 The present data demonstrate that miR-1 constantly increases from the early to the late phases of diabetic cardiomyopathy, thus mirroring an opposite trend of Pim-1. This inverse association is strengthened by the notion that Pim-1 is a direct target of miR-1, as demonstrated previously. 13 Here, we newly show that miR-1 inhibition by anti-miR-1 rescues Pim-1 levels in cardiomyocytes and CPCs challenged with HG. Furthermore, both anti-miR-1 and hPIM-1 plasmid restored the prosurvival signaling centered on phosphorylation of Bad and activation of Bcl-2 in cardiac cells. Intriguingly, removing the miR-1-dependent inhibition of Pim-1 resulted in elevation of phosphorylated Akt and abrogation of HGinduced cardiac apoptosis. This is consistent with the possibility that miR-1 impinges on cardiac cell viability through redundant molecular pathways. Accordingly, miR-1 reportedly inhibits IGF-1 19 and heat shock protein-60, 25 thereby leading to negative modulation of phosphatidylinositol 3-kinase/Akt/Bcl-2. In line with the existence of an autoregulatory circuit upstream of Pim-1, active Akt phosphorylates and inhibits Foxo3a, thereby reducing the transcription of miR-1. Thus, in the diabetic heart, miR-1 
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Pim-1 and Diabetic Cardiomyopathy could inhibit prosurvival signaling by directly interfering with Pim-1 transcription and overriding the Pim-1-activator, Akt. The finding challenged us to attempt a new gene therapy approach that targets Pim-1 for prevention of DM-induced contractile dysfunction. Echocardiography and pulsed Doppler analyses have documented the functional benefit of Pim-1 gene therapy. Furthermore, histological studies have pinpointed the prevention of interstitial fibrosis and cardiomyocyte apoptosis as major determinants in the improvement of diastolic function and preservation of contractility. Adult cardiomyocytes express 2 MHC isoforms, ␣-MHC and ␤-MHC, with the former having higher ATPase activity. The ratio of ␣-MHC to ␤-MHC correlates directly with overall cardiac performance and is remarkably reduced early in the course of diabetic cardiomyopathy. 22 Forced expression of Pim-1 resulted in restoration of proper ␣-MHC levels in diabetic hearts, which may contribute to improved contractile function. Furthermore, Pim-1 could enhance cardiac performance through preservation of sarcoendoplasmic reticulum Ca 2ϩ -ATPase, as demonstrated by us here and by others in pressure-overload models. 6 A recent study indicates that Pim-1 overexpression protects mitochondrial integrity in cardiomyocytes after ischemia/reperfusion by preventing the swelling induced by Ca 2ϩ overload and inhibiting the translocation of proapoptotic proteins from the cytosol to the outer mitochondrial membrane to mediate cytochrome c release. 7 The present data showing the ability of Pim-1 to inhibit caspase-9 specifically but not caspase-8 pinpoints a mitochondrial-mediated mechanism of cardiomyocyte protection. Preservation of mitochondrial function is also relevant to maintenance of physiological levels of reactive oxygen species. The present results indicate a blunted increase of reactive oxygen species levels in hPIM-1 -overexpressing diabetic hearts, which suggests that Pim-1 can interfere with reactive oxygen species formation. This may additionally account for reduced cardiomyocyte apoptosis after Pim-1 gene therapy. Consistent with the present data, recent findings indicate that Pim-1 protects against oxidative stress-induced apoptosis by inhibiting apoptosis signaling kinase-1 and the caspase-3 cascade. 26 CPCs genetically engineered to express hPIM-1 showed improved viability and proliferative capacity, which are essential prerequisites for myocardial homeostasis and repair. 27 We have shown here that Pim-1 gene therapy not only increased the prevalence of c-kit ϩ cells that were depleted by diabetes, but it also reduced the fraction of CPCs affected by senescence processes, which are a typical feature of diabetic cardiomyopathy. Pim-1 also increased the index of proliferation in diabetic heart. These data demonstrate the ability of Pim-1 to preserve the endogenous regenerative potential of CPCs in spite of persistent hyperglycemia. Furthermore, Pim-1 is necessary for vascular smooth muscle proliferation, 28 and CPCs engineered with Pim-1 have been shown to promote neovascularization in a mouse infarct model. 27 The present data showing the expression of hPIM-1 in vascular smooth muscle cells provide a key for interpretation of the preserved arteriole density in hPIM-1-transduced diabetic hearts. In contrast, endothelial cells were not transduced after Pim-1 gene therapy, which suggests that the improved capillary density may be due to transmission of prosurvival signals from cardiomyocytes to neighboring endothelial cells.
One important aspect of the present study is the use of a new cardiotropic vector. After systemic injection of AAV9 -hPIM-1, we found the hPIM-1 transgene to be persistently and specifically expressed in cardiac cells and skeletal myocytes, thus insuring against the possible off-target effects of the proto-oncogene. Biochemical measurements ruled out the possibility of an extracardiac influence on the beneficial effects seen after AAV9 -hPIM-1 treatment. The present study focused on the therapeutic action of Pim-1 in cardiomyopathy, yet based on preliminary results that showed preservation of skeletal myocyte morphology by Pim-1 (Online Figure VIII) , it would be worthwhile to investigate the possible benefit of Pim-1 on skeletal muscles, in light of the frequent association of heart failure and skeletal myopathy.
The present study provides novel evidence for a role of Pim-1 in the pathogenesis of diabetic cardiomyopathy. Pim-1 can serve as a therapeutic agent for the treatment of DMinduced cardiac damage by blunting cell death, preserving intrinsic regenerative potential, and stabilizing the protein composition of the heart's contractile machinery.
